NSE: DIVISLAB | BSE: 532488

Expensive Performer

Download real time

6474.50 342.50 (5.59%)

High volume+gain today

NSE 10 Oct, 2025 3:31 PM (IST)

171,877.6

Market Cap

Market Runner Up

0.8

Beta 1Year

Very Low volatility

Regulatory Tailwinds

Divi's Labs jumps on Friday as US Senate passes Biosecure Act banning funds for Chinese biotech cos See details

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Search Inside the pdf :

Divi's Laboratories Ltd.

29 Aug 2025

6474.50

5.59%

Steady performance amid near-term headwinds; structural levers intact

Accumulate: Divi's Laboratories Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -14.9%/-22.7%, respectively, as we factor in subdued growth traction in Generic API segment, lower other income and higher depreciation expenses on account of higher investments in its facilities.

Number of FII/FPI investors increased from 922 to 990 in Jun 2025 qtr.

Divi's Laboratories Ltd.

07 Aug 2025

6474.50

5.59%

Divi's Laboratories (DIVI IN) Q1FY26 Result Update Margin...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories (DIVI) Q1FY26 EBITDA was 4% below our estimates led by lower margins despite higher CS revenues. We expect margins to improve, led by better product mix and stable raw material prices. Mgmt. suggested that moderation of raw material prices, increasing RFP's and commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. Our FY26E/FY27E EPS estimates stand marginally reduced by 3-4%. We expect 20% EBITDA CAGR and 12% PAT CAGR over FY25-27E. At CMP,...

Divi's Laboratories Ltd. is trading at high volume of 1.7M with price gain of 5.59.

Divi's Laboratories Ltd.

19 May 2025

6474.50

5.59%

Divi's Laboratories (DIVI IN) Q4FY25 Result Update Margin...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories (DIVI) Q4FY25 EBITDA beat our estimates led by higher gross margin (62%; up 200 bps QoQ). We expect GMs to sustain, led by better product mix and stable raw material prices. Mgmt. suggested that moderation of raw material prices, increasing RFP's and commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. Our FY26E/FY27E EPS estimates broadly remain unchanged. We expect 22% EBITDA CAGR and 15% PAT CAGR over FY25-27E. At CMP, stock is trading at...

Divi's Laboratories Ltd. is trading at high volume of 1.7M with price gain of 5.59.

Divi's Laboratories Ltd.

25 Mar 2025

6474.50

5.59%

DIVI' S LAB

Hold: Divi's Laboratories Ltd.

Target

Geojit BNP Paribas

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

04 Feb 2025

6474.50

5.59%